大剂量口服与静脉注射甲基泼尼松龙治疗多发性硬化症复发的相似生物学效应。
Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses.
作者信息
Grau-López L, Teniente-Serra A, Tintoré M, Rovira A, Ramió-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervás J V, Martínez-Cáceres E M, Ramo-Tello C
机构信息
Hospital Germans Trias i Pujol, Badalona, Spain/Universitat Autònoma de Barcelona, Spain
Hospital Germans Trias i Pujol, Badalona, Spain/Universitat Autònoma de Barcelona, Spain.
出版信息
Mult Scler. 2015 Apr;21(5):646-50. doi: 10.1177/1352458514546786. Epub 2014 Aug 21.
UNLABELLED
Our aim was to investigate differences in immune mechanisms in multiple sclerosis (MS) relapse, after high-dose oral methylprednisolone (oMP) or intravenous methylprednisolone (ivMP). We measured serum cytokines (IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α and IFN-γ) in 39 of 49 MS patients with moderate-severe relapse, whom were treated with ivMP or oMP in a placebo-controlled, non-inferiority clinical trial. We assessed these cytokine levels at baseline and at 1 and 4 weeks post-treatment. The cytokine levels between oMP and ivMP were similar at any time. Proinflammatory cytokines (IL-6 and IFN-γ) were significantly decreased in both groups at week 1 (p = 0.05 / p = 0.03) and at week 4 (p = 0.04 / p = 0.05). This study provides further confirmatory evidence that oMP is not inferior to ivMP.
TRIAL REGISTRATION
clinicaltrials.gov identifier: NCT00753792.
未标注
我们的目的是研究在多发性硬化症（MS）复发时，大剂量口服甲基泼尼松龙（oMP）或静脉注射甲基泼尼松龙（ivMP）后免疫机制的差异。我们在49例中重度复发的MS患者中的39例中测量了血清细胞因子（IL-2、IL-4、IL-6、IL-10、IL-17、TNF-α和IFN-γ），这些患者在一项安慰剂对照的非劣效性临床试验中接受了ivMP或oMP治疗。我们在基线以及治疗后1周和4周评估了这些细胞因子水平。在任何时间点，oMP和ivMP之间的细胞因子水平相似。两组在第1周（p = 0.05 / p = 0.03）和第4周（p = 0.04 / p = 0.05）时促炎细胞因子（IL-6和IFN-γ）均显著降低。本研究提供了进一步的确证证据，表明oMP并不劣于ivMP。
试验注册
clinicaltrials.gov标识符：NCT00753792。
Zotero 插件